Future multibillion-dollar obesity market will be dominated by Novo and Lilly, bank predicts

Players are beginning to position themselves as a very lucrative market for weight-loss drugs matures, but Morgan Stanley believes the two rivals Novo Nordisk and Eli Lilly will take almost half.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

Eli Lilly, Amgen, and a number of other companies are seeking to challenge Novo Nordisk on the obesity market, which is facing a demand boom in coming years, investment bank Morgan Stanley assesses according to media Financial Times.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading